Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Adverse Events Following Trivalent Inactivated Influenza Vaccination in Children: Analysis of the Vaccine Adverse Event Reporting System.

Muhammad R, Haber P, Broder K, Leroy Z, Ball R, Braun MM, Davis RL, McMahon AW.

Pediatr Infect Dis J. 2011 Jan;30(1):e1-8. doi: 10.1097/INF.0b013e3181ff9795. Review.

PMID:
21042229
2.
3.

Adverse events after Fluzone ® Intradermal vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2011-2013.

Moro PL, Harrington T, Shimabukuro T, Cano M, Museru OI, Menschik D, Broder K.

Vaccine. 2013 Oct 9;31(43):4984-7. doi: 10.1016/j.vaccine.2013.08.001. Epub 2013 Aug 29.

PMID:
23994022
4.

Safety and tolerability of a 2009 trivalent inactivated split-virion influenza vaccine in infants, children and adolescents.

Lambert SB, Chuk LM, Nissen MD, Nolan TM, McVernon J, Booy R, Heron L, Richmond PC, Walls T, Marshall HS, Reynolds GJ, Hartel GF, Hu W, Lai MH.

Influenza Other Respir Viruses. 2013 Sep;7(5):676-85. doi: 10.1111/irv.12107. Epub 2013 Apr 2.

5.
6.

Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6-23 months of age.

Rosenberg M, Sparks R, McMahon A, Iskander J, Campbell JD, Edwards KM.

Vaccine. 2009 Jul 9;27(32):4278-83. doi: 10.1016/j.vaccine.2009.05.023. Epub 2009 May 28.

PMID:
19450636
7.

Ontology-based combinatorial comparative analysis of adverse events associated with killed and live influenza vaccines.

Sarntivijai S, Xiang Z, Shedden KA, Markel H, Omenn GS, Athey BD, He Y.

PLoS One. 2012;7(11):e49941. doi: 10.1371/journal.pone.0049941. Epub 2012 Nov 28.

8.

Postlicensure safety surveillance for high-dose trivalent inactivated influenza vaccine in the Vaccine Adverse Event Reporting System, 1 July 2010-31 December 2010.

Moro PL, Arana J, Cano M, Menschik D, Yue X, Lewis P, Haber P, Martin D, Broder K.

Clin Infect Dis. 2012 Jun;54(11):1608-14. doi: 10.1093/cid/cis256. Epub 2012 Mar 22.

PMID:
22441652
9.

Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.

Haber P, Moro PL, McNeil MM, Lewis P, Woo EJ, Hughes H, Shimabukuro TT.

Vaccine. 2014 Nov 12;32(48):6499-504. doi: 10.1016/j.vaccine.2014.09.018. Epub 2014 Sep 22.

PMID:
25258101
10.
11.

Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010.

Vellozzi C, Broder KR, Haber P, Guh A, Nguyen M, Cano M, Lewis P, McNeil MM, Bryant M, Singleton J, Martin D, DeStefano F.

Vaccine. 2010 Oct 21;28(45):7248-55. doi: 10.1016/j.vaccine.2010.09.021. Epub 2010 Sep 16.

PMID:
20850534
12.

Randomized trial to compare the safety and immunogenicity of CSL Limited's 2009 trivalent inactivated influenza vaccine to an established vaccine in United States children.

Brady RC, Hu W, Houchin VG, Eder FS, Jackson KC, Hartel GF, Sawlwin DC, Albano FR, Greenberg M.

Vaccine. 2014 Dec 12;32(52):7141-7. doi: 10.1016/j.vaccine.2014.10.024. Epub 2014 Oct 29.

PMID:
25454878
13.

Post-licensure surveillance of quadrivalent live attenuated influenza vaccine United States, Vaccine Adverse Event Reporting System (VAERS), July 2013-June 2014.

Haber P, Moro PL, Cano M, Lewis P, Stewart B, Shimabukuro TT.

Vaccine. 2015 Apr 15;33(16):1987-92. doi: 10.1016/j.vaccine.2015.01.080. Epub 2015 Feb 9.

PMID:
25678241
14.

Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.

Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, Haber P, Pless RP, Mootrey G, Ellenberg SS, Braun MM, Chen RT.

MMWR Surveill Summ. 2003 Jan 24;52(1):1-24. Erratum in: MMWR Morb Mortal Wkly Rep. 2003 Feb 14;52(06):113.

15.

Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2009 Dec 11;58(48):1351-6.

16.

Risk of confirmed Guillain-Barre syndrome following receipt of monovalent inactivated influenza A (H1N1) and seasonal influenza vaccines in the Vaccine Safety Datalink Project, 2009-2010.

Greene SK, Rett M, Weintraub ES, Li L, Yin R, Amato AA, Ho DT, Sheikh SI, Fireman BH, Daley MF, Belongia EA, Jacobsen SJ, Baxter R, Lieu TA, Kulldorff M, Vellozzi C, Lee GM.

Am J Epidemiol. 2012 Jun 1;175(11):1100-9. doi: 10.1093/aje/kws195. Epub 2012 May 11.

PMID:
22582210
17.

General practice encounters following seasonal influenza vaccination as a proxy measure of early-onset adverse events.

Dey A, Gidding HF, Menzies R, McIntyre P.

Vaccine. 2014 Apr 17;32(19):2204-8. doi: 10.1016/j.vaccine.2014.02.044. Epub 2014 Mar 6.

PMID:
24613527
18.

Serious adverse events following receipt of trivalent inactivated influenza vaccine in Korea, 2003-2010.

Choe YJ, Cho H, Kim SN, Bae GR, Lee JK.

Vaccine. 2011 Oct 13;29(44):7727-32. doi: 10.1016/j.vaccine.2011.07.129. Epub 2011 Aug 7.

PMID:
21827815
19.

Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis.

Salmon DA, Proschan M, Forshee R, Gargiullo P, Bleser W, Burwen DR, Cunningham F, Garman P, Greene SK, Lee GM, Vellozzi C, Yih WK, Gellin B, Lurie N; H1N1 GBS Meta-Analysis Working Group.

Lancet. 2013 Apr 27;381(9876):1461-8. doi: 10.1016/S0140-6736(12)62189-8. Epub 2013 Mar 13.

PMID:
23498095
20.

Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study.

Langley JM, Scheifele DW, Quach C, Vanderkooi OG, Ward B, McNeil S, Dobson S, Kellner JD, Kuhn S, Kollman T, MacKinnon-Cameron D, Smith B, Li Y, Halperin SA.

Vaccine. 2012 May 14;30(23):3389-94. doi: 10.1016/j.vaccine.2012.03.046. Epub 2012 Mar 30.

PMID:
22469860

Supplemental Content

Support Center